Radixact Synchrony: Preliminary Clinical Experience from ...
Transcript of Radixact Synchrony: Preliminary Clinical Experience from ...
![Page 1: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/1.jpg)
Radixact Synchrony: Preliminary Clinical Experience from University of Turin
Umberto Ricardi
University of Turin
![Page 2: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/2.jpg)
Department of Oncology – Radiation Oncology AOU Città della Salute e della Scienza di Torino
![Page 3: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/3.jpg)
Department of Oncology – Radiation Oncology
AOU Città della Salute e della Scienza di Torino
18 RO
16 Residents
9 MP
2 Dosimetrists
22 RTT
3000 new patients per year; 450 brachy procedures
![Page 4: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/4.jpg)
• Technological advances in treatment planning and delivery provide unique opportunities for improving effectiveness of RT
• Absolute “radioresistance” does not exist: treatment failure occurs if and only if… – the biologically equivalent dose is not
sufficiently high OR … – there is disease outside the high-dose volume
Radiation therapy is Precision Medicine
![Page 5: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/5.jpg)
• Halperin’s first rule of pediatric radiation oncologist
−Don’t miss the tumor
• Halperin’s second rule of pediatric radiation oncologist- a corollary to the first rule
– In general, most tumors are radioresistant if they are not in treatment beam
![Page 6: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/6.jpg)
![Page 7: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/7.jpg)
Notable Treatment Sites Thorax Abdomen (liver, pancreas, etc.) Popular Management Strategies • Free breathing PTV expansion (larger volumes)
• Motion reduction Abdominal compression or breath holding
• Beam Gating/ABC treat only during specific times of the
respiratory cycle
• Real time motion compensation Dynamic tumor tracking
SABR
Motion Management Sites and Techniques
![Page 8: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/8.jpg)
Conventional (ITV-PTV based) • Contour and treat full tumor
Accelerator beam gating • Patient breathes normally;
beam only on while patient is in a certain phase of the respiratory cycle
Active breathing control • Patient holds breath in a
certain position; beam only on in that phase of the respiratory cycle
Dynamic tumor tracking • Patient breathes normally;
tumor is tracked; beam always on and moves with tumor
Respiratory Motion Management
![Page 9: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/9.jpg)
Key challenge: Hitting moving targets
Current “motion management” for precise RT
![Page 10: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/10.jpg)
Motion Management Objectives
![Page 11: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/11.jpg)
Do you account for motion? Do you ignore motion?
Do you compensate for it?
Do you synchronize with it?
![Page 12: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/12.jpg)
Motion assessment (4D-CT) VMAT Image guidance (4D CBCT)
Enablers of Technologically Targeted RT
UNIVERSITA’ DEGLI STUDI DI TORINO
ALL FACILITATING SABR
Breath cycle
![Page 13: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/13.jpg)
Stereotactic Body Radiation Therapy (SBRT) Stereotactic ABlative Radiotherapy (SABR)
A technique for delivering external beam radiotherapy o with a high degree of accuracy to an extra-cranial target, o using high doses of irradiation, o in 1-8 treatment fractions
S. Senan, U. Ricardi, M. Guckemberger, K.E. Rosenzweig, and N. Ohri: Stage I NSCLC and oligometastatic disease The IASLC Multidisciplinary approach to Thoracic Oncology, 2017
![Page 14: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/14.jpg)
[Ricardi et al, Phys Med 2017]
![Page 15: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/15.jpg)
ESMO Guidelines (Postmus PE et al, Annals of Oncology 2017) • SABR is the non-surgical treatment of choice for stage I NSCLC
(BED>100 Gy) ASTRO Guidelines (Videtic GMM et al, PRO 2017) • SABR delivers ablative doses in 1 to 5 fractions • Schedules using from 6 to 10 fractions with a BED of > 100 Gy
with stereotactic tehniques are also possible
NCCN Guidelines (Version 8. 2020) • SABR is recommended in stage I-IIA for patients medically
inoperable or who refuse to have surgery • SABR is also an appropriate option for patients with high
surgical risk
SABR: guidelines
![Page 16: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/16.jpg)
UNIVERSITA’ DEGLI STUDI DI TORINO
SABR in oligometastatic disease
Treat metastatic disease for cure (or at least significant prolongation of survival)
New indication for radiotherapy
Unlike surgery, SABR works in concert with systemic therapy
Not as COSTLY vs. surgery in toxicity and invasiveness
More palatable for those who ultimately progress
![Page 17: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/17.jpg)
Potential SABR Toxicity Depends on Tumor Site
• Fatigue
• Rib fracture, chest wall pain
• Skin Erythema/fibrosis
• Fatigue • Pneumonitis, atelectasis
hemoptysis, fibrosis • Rib fracture, chest wall pain
![Page 18: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/18.jpg)
54 Gy /3 fr T1 lesions, not adjacent to chest wall
60 Gy/8 fr central lesions with limited overlap with mediastinum (50 Gy/10fr ultracentral lesions- selected patients)
55 Gy /5 fr or 50 Gy/5 fr T1 lesions with broad chest wall contact, and T2 lesions
«Risk adapted» protocol @ University of Turin
![Page 19: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/19.jpg)
Lung SABR protocol @ University of Turin
![Page 20: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/20.jpg)
MANDATORY (minimum) REQUIREMENTS RECOMMENDED
Equipment Staff training Patient selection Treatment
planning Dose-
fractionation Image guidance Follow-up Quality
assurance
[Guckenberger M, Radioth Oncol 2017]
ESTRO-ACROP guidelines
![Page 21: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/21.jpg)
AverageCT CTV
Margins: 5 mm axial 10 mm CC
Treatment delivery 4DCBCT
SABR Protocol @ University of Turin
![Page 22: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/22.jpg)
respiratory surrogate: abdominal pressure piezo-electric belt
4DCT accurately compensate for target motion and define patient’s specific internal margins
Virtual simulation- 4DCT
![Page 23: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/23.jpg)
Technical Advances may have an impact on safety and efficacy
![Page 24: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/24.jpg)
July 2019
![Page 25: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/25.jpg)
Synchrony®: A suite of technologies that allows seamless adaptation to target and patient motion in real-time during treatment delivery (July 2020)
Continuously determine the position of the moving target during treatment
Continuously reshape the treatment beam (jaw and leaf positions) to follow the target’s motion
![Page 26: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/26.jpg)
Motion Synchronization shifts the paradigm without compromise
![Page 27: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/27.jpg)
Synchrony®: tracking modalities
![Page 28: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/28.jpg)
kV Imaging System Hardware For Tracking the Moving Target During Treatment
1. kV detector 2. X-ray tube 3. Generator • During treatment, collect
2D radiographs at selected gantry angles
• Locate target or surgically implanted fiducials in radiographs
![Page 29: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/29.jpg)
Synchrony®: Treatment Room
![Page 30: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/30.jpg)
Tracking Target Motion Between Radiographs
Irregular motion (e.g., digestive) Unpredictable Assume target maintains last
measured position until next radiograph
Respiratory motion Use a camera system to track
position of markers attached to patient surface
Build a model to correlate marker positions (LED) to internal target position
Update the model each time you acquire a radiograph
Time (seconds)
Time (seconds)
Dis
plac
emen
t (m
m)
Dis
plac
emen
t (m
m)
![Page 31: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/31.jpg)
Synchrony®: Tracking the Moving Target
1. kV detector 2. X-ray tube 3. Generator
• During treatment, the system collect 2D radiographs at selected gantry angles
• The target or surgically implanted fiducials are located in radiographs
• Synchrony builds a model to correlate marker (LED) position to internal target position:
updating the model each time radiographs are acquired
Continously reshaping the treatment beam (jaws and leave) to follow the target motion
![Page 32: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/32.jpg)
![Page 33: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/33.jpg)
Synchrony® decision chart
![Page 34: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/34.jpg)
Synchrony®: patients selection
Target
Size < 5-7 cm diameter (sphere) Shape Regular, should persist over the
course of treatment Motion < 2 cm along each translational
axis Tracking Target
Density Higher than the surrounding tissue
Visualization Available imaging angles where it’s not significantly obscured by structures
![Page 35: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/35.jpg)
University of Torino: patients’ selection Single nodule
Peripherally located > 3 cm diameter
![Page 36: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/36.jpg)
• 84 yo, man, PS 1 ECOG • Smoker • COPD (stage II GOLD) May 2020: Cough and hemophtysis Chest X-Ray: opacity in right upper lobe Total body CT scan (June 2020) Right upper parenchymal tumor (max diam 48 mm); no other pathologic findings CT-PET scan (July 2020): pathologic uptake in the right upper lobe lesion (SUVmax: 12)
Our first patient (July 2020) – Clinical History
![Page 37: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/37.jpg)
![Page 38: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/38.jpg)
First patient – Clinical History
• FEV1: 1,24 l (54%); FVC: 3.25 L (105%); DLCO: 55%
• PO2: 68.5; PCO2: 43.4; pH: 7.4
• CT-guided FNAB: not feasible (poor respiratory function, comorbidity, site) • Bronchoscopy: no evidence of endobronchial lesion; BAL negative
«Clinical proof of malignancy», not biopsy proven Stage IIA NSCLC (cT2bN0M0), right upper lobe Not amenable with surgery (poor respiratory function) SABR
![Page 39: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/39.jpg)
respiratory surrogate: abdominal pressure piezo-electric belt
4DCT accurately compensate for target motion and define patient’s specific internal margins
Virtual simulation- 4DCT
![Page 40: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/40.jpg)
Breath Cycle
![Page 41: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/41.jpg)
TRACKING TARGET VOLUME
Contouring GTV phase 30%
![Page 42: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/42.jpg)
Radixact
50 Gy = 10 Gy times 5 (80% isodose) Thoracic Stereotactic Ablative RT: Synchrony
Tumor PTV: 45x60x45mm GTV to PTV: 3mm Tumor Motion: around 5-7mm (AP) PTV (ITV): 60.78 cc vs PTV (Sync): 57.23 cc
![Page 43: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/43.jpg)
• 71 yo, female, PS 0 ECOG • No smoker • COPD (stage I GOLD) December 2018: diagnosis of adenocarcinoma, right upper lobe, stage IV (M1a-pleural nodules) Molecular analysis: ALK nt, ROS1 nt, PDL1 0%, EGFR mut (ex 19) 9/4/2019: Osimertinib
July 2020: oligoprogressive disease (single nodule, right upper lobe, max diam 33 mm)
Second patient – Clinical History
![Page 44: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/44.jpg)
TRACKING TARGET VOLUME
Contouring GTV phase 30%
![Page 45: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/45.jpg)
50 Gy = 10 Gy times 5 (80% isodose)
Thoracic Stereotactic Ablative RT: Synchrony
Tumor PTV: 30x60x33mm GTV to PTV 3mm Tumor motion: 5-7mm (AP) PTV (ITV): 32 cc PTV (Sync): 26.1 cc V40 Bronchial Tree (VMAT): 1.37 cc V40 Bronchial Tree (Radixact): 0.5 cc
Radixact
![Page 46: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/46.jpg)
September 2020- November 2020: 3 patients treated with Synchrony (total: 5 patients)
V. D., 83 yo, female, PS 0 ECOG • Previous history of widely resected thigh SCC (with left inguinal adenopathy,
treated with exclusive RT) • November 2019: nodule in right upper lobe (not biopsy proven), PET + • Observation • PET-CT (september 2020): CR inguinal region, PD right upper lobe (SUVmax 6), diam 33 mm
![Page 47: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/47.jpg)
50 Gy in 5 fx (80% isodose)
Thoracic Stereotactic Ablative RT: Synchrony
Radixact
![Page 48: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/48.jpg)
A. L., 77 yo, female, PS 0 ECOG • Previous rhabdomyosarcoma (left
thigh) treated with surgery + RT • September 2020: metastatic
pulmonary lesion • CT whole body (10/2020): PD ML
nodule (30 mm)
![Page 49: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/49.jpg)
50 Gy in 5 fractions (80% isodose)
Thoracic Stereotactic Ablative RT: Synchrony
Radixact
![Page 50: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/50.jpg)
L. L., 75 yo, male, PS 0 ECOG • Previous urothelial bladder cancer • November 2020: diagnosis of nodule in left upper lobe (not biopsy
proven), PET + (SUVmax 7.5), 30 mm diam • No surgical indication (respiratory function)
![Page 51: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/51.jpg)
55 Gy = 11 Gy times 5 (80% isodose)
Thoracic Stereotactic Ablative RT: Synchrony
Radixact
Left Brachial Plexus: Dmax (0.03 cc): 29.8 Gy Linac vs 28.6 Radixact
![Page 52: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/52.jpg)
Synchrony: delivery workflow
Patient must be informed about all the processes they will undergo during RT • RESPIRATORY TRAINING before CT
simulation
• Patient should maintain NATURAL BREATH Synchrony will be able to build a provisional model more easily
![Page 53: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/53.jpg)
Synchrony: delivery workflow
![Page 54: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/54.jpg)
Synchrony: delivery workflow
SIMULATION To test Synchrony capability to buid a predictive model referred to patient’s respiratory pattern Treatment beam is disabled You can acquire MVCT followed by KV images (2D radiographs) in order to check target motion
To test: JAWS MLC LEAVES GANTRY ROTATION COUCH MOVEMENT
![Page 55: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/55.jpg)
Synchrony: delivery workflow
SIMULATION allows to verify: SYNCHRONY CAPABILITY to predict target position 2D RADIOGRAPHS CONSISTENCY (angles are settled
during planning): Rx should be able to show the target among different structures (up to 6 Rx per gantry rotation)
Patient’s COMPLIANCE
SCORE WHEEL: Angles in which the target is well visualized (planning phase)
![Page 56: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/56.jpg)
Synchrony: delivery workflow
LIGHT BOX connected to the COUCH
CABLES from Light Box connected to LED markers
![Page 57: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/57.jpg)
At least
TWO OF THE THREE MARKERS MUST BE VISIBLE
to the camera at all times
Synchrony: delivery workflow
LED MARKERS placed on patient’s thorax (respiratory movement)
![Page 58: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/58.jpg)
Synchrony: delivery workflow
REFERENCE POST LED marker attached to the couch TO EXCLUDE COUCH MOTION IN LED AMPLITUDE GRAPHIC
![Page 59: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/59.jpg)
Synchrony: delivery workflow MV CT acquisition register match check position corrections couch moves
![Page 60: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/60.jpg)
Synchrony: delivery workflow
o LED well placed and visualized
o Regular breathing pattern
o MVCT less than 1 min
![Page 61: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/61.jpg)
Radixact is ready to treat
Synchrony: delivery workflow
The localization algorithm searches
within this region on the radiographs to identify
the target
PREPARE to acquire Kv Images in order to build model
![Page 62: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/62.jpg)
Model was built in LESS THAN 1 MIN
Jaws and MLC leaves
ADAPTED TO TARGET
•Target WELL VISUALIZED throughout the treatment
BUILD MODEL
Synchrony: delivery workflow
![Page 63: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/63.jpg)
Target Visualization
Synchrony: delivery workflow
![Page 64: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/64.jpg)
POTENTIAL DIFF THE QUALITY OF THE MODEL
Increases if the patient’s breathing cycle does not fit the
model well
MEASURED Δ MODEL ACCURACY
Patient is not breathing predictably
Parameters
Synchrony: delivery workflow
![Page 65: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/65.jpg)
Synchrony: delivery workflow
![Page 66: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/66.jpg)
Treatment workflow 1° patient (in room time: 24 minutes)
Treatment workflow 1° patient (in room time: 22 minutes)
![Page 67: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/67.jpg)
Follow up
July 2020 October 2020
![Page 68: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/68.jpg)
Synchrony®: Pulmonary Target Tracking Conclusions Easy to use/ Reliable Patient’s selection is crucial in this phase of clinical
implementation Useful to reduce exposure of healthy tissues and
improving safety of curative treatment also in patients more clinically fragile (elderly, poor respiratory function) maybe also for ”Hybrid treatment”: SABR + moderately hypofx on mediastinum
![Page 69: Radixact Synchrony: Preliminary Clinical Experience from ...](https://reader030.fdocuments.net/reader030/viewer/2022012014/615916d4453f5e5eea662ffb/html5/thumbnails/69.jpg)
Synchrony® at Turin University
Prostate
Liver, Pancreas
Lung SABR
Productivity, Flexibility, Reliability